Assessment of cardiovascular risk in HIV-positive individuals with latent tuberculosis infection
Objective. Assessment of cardiovascular risk in HIV-positive individuals with latent tuberculosis infection (LTBI).Kulabukhova E.I., Khokhlova O.N., Pokrovskaya A.V., Shilov A.M., Kozyrina N.V., Popova A.A., Kanestri V.G., Goliusova M.D., Kravchenko A.V.
Materials and methods. Screening for tuberculosis infection was performed in 395 patients with HIV infection followed-up in the AIDS Consultation and Diagnostic Department of the Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being. A positive result was obtained in 75 (19%) people. From these patients, the study group of 39 people with HIV and LTBI was formed. Control group included HIV-infected patients without LTBI, matching in gender, age, smoking status and antiretroviral therapy regimen with study group. Lipid profile parameters, ten-year risk of fatal and non-fatal cardiovascular events according to the SCORE2 scale, comorbidities, relative number of classical (CD14++CD16-), inflammatory (CD14++CD16+) and non-classical (CD14+CD16++) monocytes were analyzed in the groups.
Results. High risk according to the SCORE2 scale was found in 68% of the study group and 57% of the control group, very high risk – 28 and 32%, respectively. Arterial hypertension was found in 31% of the study group and 24% of the control group, metabolic syndrome – 17 and 5%. The CD14++CD16- monocytes level was higher than normal in 67% of patients in the sudy group and in 82% in the control group, and CD14+CD16++ were lower than normal in 97 and 100% of patients, respectively.
Conclusion. No statistically significant differences were found between the groups, however, it cannot be ruled out that LTBI is an additional factor contributing to atherogenesis in patients with HIV infection.
Keywords
HIV infection
latent tuberculosis infection
cardiovascular risk
monocyte subpopulations
References
1. Liu X., Li F., Niu H., Ma L., Chen J., Zhang Y. et al. IL-2 restores T-Cell dysfunction induced by persistent Mycobacterium tuberculosis antigen stimulation. Front Immunol. 2019; 10: 2350. DOI: 10.3389/fimmu.2019.02350
2. Wagle A., Goerlich E., Post W.S., Woldu B., Wu K.C., Hays A.G. HIV and Global Cardiovascular Health. Curr. Cardiol. Rep. 2022; 24(9): 1149–57. DOI: 10.1007/s11886-022-01741-1
3. Djaharuddin I., Amir M., Qanitha A. Exploring the link between cardiovascular risk factors and manifestations in latent tuberculosis infection: a comprehensive literature review. Egypt Heart J. 2023; 75(1): 1–9. DOI: 10.1186/s43044-023-00370-5
4. Hossain M.B., Johnston J.C., Cook V.J., Sadatsafavi M., Wong H., Romanowski K. et al. Role of latent tuberculosis infection on elevated risk of cardiovascular disease: a population-based cohort study of immigrants in British Columbia, Canada, 1985–2019. Epidemiol. Infect. 2023; 151: 1–8. DOI: 10.1017/S0950268823000559
5. Huaman M.A., De Cecco C.N., Bittencourt M.S., Ticona E., Kityo C., Ballena I. et al. Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda. Clin. Infect. Dis. 2021; 73(9): e3384–90. DOI: 10.1093/cid/ciaa1934
6. Ziegler-Heitbrock L., Hofer T.P. Toward a refined definition of monocyte subsets. Front Immunol. 2013; (4): 23. DOI: 10.3389/fimmu.2013.00023
7. Нозадзе Д.Н., Рвачева А.В., Казначеева Е.И., Сергиенко И.В. Моноциты в развитии и дестабилизации атеросклеротической бляшки. Атеросклероз и дислипидемии 2012; 3(8): 25–36.
Nozadze D.N., Rvacheva A.V., Kaznacheeva E.I., Sergienko I.V. [Monocytes in the development and destabilization of atherosclerotic plaques]. Journal of Atherosclerosis and Dyslipidemias 2012; (3): 25–36. (In Russ.).
8. Wildgruber M., Aschenbrenner T., Wendorff H., Czubba M., Glinzer A., Haller B. et al. The «Intermediate» CD14++CD16+ monocyte subset increases in severe peripheral artery disease in humans. Sci. Rep. 2016; (6): 39483. DOI: 10.1038/srep39483
9. Ruder A.V., Wetzels S.M.W., Temmerman L., Biessen E.A.L., Goossens P.. Monocyte heterogeneity in cardiovascular disease. Cardiovasc. Res. 2023; 119(11): 2033–45. DOI: 10.1093/cvr/cvad069
10. Feria M.G., Chang C., Ticona E., Moussa A., Zhang B., Ballena I. et al. Pro-Inflammatory Alterations of Circulating Monocytes in Latent Tuberculosis Infection. Open Forum Infect. Dis. 2022; 9(12): ofac629. DOI: 10.1093/ofid/ofac629
11. Wang P.H., Wu M.F., Hsu C.Y., Lin S.Y., Chang Y.N., Lee H.S. et al. The Dynamic Change of Immune Checkpoints and CD14+ Monocytes in Latent Tuberculosis Infection. Biomedicines 2021; 9(10): 1479. DOI: 10.3390/biomedicines9101479
12. Huaman M.A., Juchnowski S.M., Zidar D.A., Kityo C.M., Nalukwago S., Nazzinda R. et al. Monocyte activation in persons living with HIV and tuberculosis coinfection. AIDS 2021; 35(3): 447–52. DOI: 10.1097/QAD.0000000000002766
13. Каминская Г.О., Абдуллаев Р.Ю. Туберкулез и обмен липидов. Туберкулез и болезни легких 2016; 94(6): 53–63. DOI: 10.21292/2075-1230-2016-94-6-53-63
Kaminskaya G.O., Аbdullaev R.Yu. [Tuberculosis and lipid exchange]. Tuberculosis and Lung Diseases 2016; 94(6): 53–63. (In Russ.). DOI: 10.21292/2075-1230-2016-94-6-53-63
14. Han J., Wang B., Han N., Zhao Y., Song C., Feng X. Mao Y. et al. CD14(high)CD16(+) rather than CD14(low)CD16(+) monocytes correlate with disease progression in chronic HIV-infected patients. J. Acquir. Immune Defic. Syndr. 2009; 52(5): 553–9. DOI: 10.1097/qai. 0b013e3181c1d4fe
About the Authors
Ekaterina I. Kulabukhova, Cand. Med. Sci., Assistant, Department of Infectious Diseases with Courses of Epidemiology and Phthisiology, Medical Institute, Patrice Lumumba Peoples’ Friendship University of Russia, Infectiologist, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; ekulabukhova@mail.ru; https://orcid.org/0000-0003-3645-7275Olga N. Khokhlova, Cand. Med. Sci., Head, Clinical and Laboratory Group, Doctor of Clinical Laboratory Diagnostics, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; xoxlova@cmd.su; https://orcid.org/0000-0001-9736-4043
Anastasia V. Pokrovskaya, MD, Senior Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Associate Professor, Department of Infectious Diseases with Courses of Epidemiology and Phthisiology, Medical Institute, Patrice Lumumba Peoples’ Friendship University of Russia, Moscow, Russia; pokrovskaya@cmd.su; https://orcid.org/0000-0002-2677-0404
Andrey M. Shilov, Graduate Student, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Assistent, Department of Infectious Diseases with Courses of Epidemiology and Phthisiology, Medical Institute, Patrice Lumumba Peoples’ Friendship University of Russia, Moscow, Russia; sh_andrey_max@mail.ru; https://orcid.org/0009-0000-7966-9708
Nadezhda V. Kozyrina, Cand. Med. Sci., Senior Researcher, Department of Epidemiology and Prevention of AIDS, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being, Moscow, Russia; nad-kozyrina@yandex.ru; htpp://orcid.org/0000-0001-5134-0054
Anna A. Popova, Cand. Med. Sci., Senior Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Associate Professor, Department of Infectious Diseases, Russian Medical Academy of Continuous Professional Education; popova@cmd.su; https://orcid.org/ 0000-0001-9484-5917
Veronika G. Kanestri, MD, Senior Researcher, Infectiologist, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being, Moscow, Russia; kanestri@yandex.ru: https://orcid.org/0000-0002-2234-7094
Marina D. Goliusova, Infectiologist, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; mad2501@yandex.ru; https://orcid.org 0000-0002-5325-6857
Professor Alexey V. Kravchenko, MD, Leading Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; alexey-kravtchenko@yandex.ru; http://orcid.org/0000-0001-7857-3763
Similar Articles
